Mohammad Hassan Nazaran et al., J <strong>Vaccines</strong> Vaccin <strong>2013</strong>, 4:5http://dx.doi.org/10.4172/2157-7560.S1.0183 rd International Conference on<strong>Vaccines</strong> & VaccinationJuly 29-31, <strong>2013</strong> Embassy Suites Las Vegas, NV, USANanochelating technology introduces a new generation of efficient adjuvantsMohammad Hassan Nazaran 1 , Saideh Fakharzadeh 1 , Somayeh Kalanaky 1 , Maryam Hafizi 1 , Mohammad Mahdi Goya 2 , Zahra Masoumi 1 ,Maryam Abbasi 1 and Mehdi Mahdavi 11Sodour Ahrar Shargh Company, Iran2Ministry of Health of Iran, IranPrevention of hepatitis B requires a vaccine that stimulates the humoral and cellular immune responses in a balancedmanner, particularly those associated with Th1 and cytotoxic T cells. Currently alum adjuvant is used in hepatitis B vaccineformulations and lacks the efficiency of establishing such immune response. Therefore, it is essential to design a new adjuvantwith an efficient structure to stimulate a strong Th1 response. For the first time in the present study, we synthesized Hep-c nanocomplexbased on the novel nanochelating technology and evaluated its efficacy to improve the immunogenicity of the vaccineagainst hepatitis B.Balb/c female mice were injected with 10 μg/ml of hepatitis B vaccine 3 times with or without different doses of Hep-c.Total serum antibody, IgG1, IgG2a, IgG2b, IgM, anti-HBs Ag, interleukin-4 (IL-4) and interferon-gamma (IFN-γ) levels wereexamined by ELISA reader. Proliferative response of splenocytes was evaluated using BRDU assay.The splenocyte proliferation and serum HBs Ag-specific IgM and also IgG2a antibody titers in the HBsAg-immunizedmice were significantly enhanced by Hep-c. This nano-complex promoted production of IL-4 significantly and also dramaticallyincreased IFN-γ level in Hep-c treated groups compared to the control group.Our findings indicated that due to the unique structure of Hep-c, it could not only preserve alum ability to produce antibodieseffectively but also cover its inefficiency to induce Th1 response and prompt cellular immunity. Thus, this nano-adjuvant has thesuitable potential to be used in commercial HBS vaccine formulations.BiographyMohammad Hassan Nazaran is owner of Nanochelating Technology and executive manager and chairman of Management Board of Sodour AhrarShargh Company. This technology is brought up for the fi rst time in the history of science and is registered at US20120100372A1 in USPTO in theUnited States of America.mnazaran@nanochelatingtechnology.comJ <strong>Vaccines</strong> Vaccin <strong>2013</strong>ISSN: 2157-7560, JVV an open access journal<strong>Vaccines</strong>-<strong>2013</strong>July 29-31, <strong>2013</strong>Volume 4 Issue 5Page 150
Moustafa A.F. Abbas et al., J <strong>Vaccines</strong> Vaccin <strong>2013</strong>, 4:5http://dx.doi.org/10.4172/2157-7560.S1.0183 rd International Conference on<strong>Vaccines</strong> & VaccinationJuly 29-31, <strong>2013</strong> Embassy Suites Las Vegas, NV, USAComparison of tuberculin skin test (TST) and quantiferon test (QFT) for detection of latentTB infection among health care workers (HCWs) in a tertiary care hospital in Riyadh, SaudiArabiaMoustafa A. F. Abbas 2 , Nasser AE. AIHamdan 1 , Mohamed S. AIQahtani 3 , Suhail Klantan 3 , Lamiaa A. Fiala 2 and Gehad ElGhazali 3,41Community Medicine Dept., Faculty of Medicine, King Fahad Medical City, Saudi Arabia2Community Medicine Dept., Faculty of Medicine, Suez Canal University, Egypt3King Fahad Medical City, Ministry of Health, Saudi Arabia4SEHA hospital, Abu Dhabi, United Arab EmiratesBackground: Latent TB Infection is a common finding among HCWs in the middle east, that is usually discovered on routinepre-employment examination or during regular health check, it needs a course of anti-tuberculous drug medication for monthswith subsequent side effects. Tuberculin Skin Test (TST) is the traditional testing method for diagnosing LTBI, but it has a knownhigh rate of false positive with subsequent needless loss of time, efforts, loss of productivity and side effects. QFT test has a highersensitivity and specificity.Aim: To determine the sensitivity, specificity, positive and negative predictive value of TST versus QFT Test as a diagnostic toolfor latent TB among new hires of health care workers at KFMC, Riyadh, Saudi Arabia.Methods: A descriptive study of 268 new HCWs agreed to participate, questionnaire with socio-demographic data and workhistory was filled, and both test were done TST and QFT test. Recent BCG vaccination and TST result of 5 mm or less wereexcluded, since there is a low positive rate.Results: Sensitivity and specificity of TST at standard 10mm or more to be positive, was 100 % and 53.4% as compared to QFTtest. Using different cutoff measurements of size of TST indurations specificity was improved at the expense of sensitivity; at13mm or more, sensitivity, specificity and κ were 95.5%; 73.2 and 0.611 respectively; while at 15mm or more it was 74.8%; 84.1%and 0.605 respectively. Frequency distribution of sizes of induration according to QFT test results and ROC curve showed thatat 13 mm or more specificity would be improved to 70 percent approximately and sensitivity to be still at 90% approximately.Conclusion: When comparing TST and QFT, Rates of True negatives and Agreement were improved from (specificity = 53.4%)and (κ=0.536), to (Specificity=63.9%) and (κ=0.611) when using a different cut off point for induration sizes of 13 mm or more,rather than the traditional 10 mm or more cutoff point. Large scale study is required to confirm such findings in Middle Easternhealth care settings.mostafafouad@gmail.comJ <strong>Vaccines</strong> Vaccin <strong>2013</strong>ISSN: 2157-7560, JVV an open access journal<strong>Vaccines</strong>-<strong>2013</strong>July 29-31, <strong>2013</strong>Volume 4 Issue 5Page 151
- Page 1 and 2:
111 th OMICS Group ConferenceJuly 2
- Page 3 and 4:
Medical SciencesISSNAddiction Resea
- Page 5 and 6:
Impact Factors (IF) and Index Coper
- Page 7 and 8:
111 th OMICS Group Conference3 rd I
- Page 9 and 10:
Journal of Clinical & Cellular Immu
- Page 11 and 12:
111 th OMICS Group Conference3 rd I
- Page 13 and 14:
111 th OMICS Group Conference3 rd I
- Page 15 and 16:
Clinical Microbiology-2013OMICS Gro
- Page 17 and 18:
Immunology Summit-2013OMICS Group i
- Page 19 and 20:
Probiotics-2013OMICS Group is organ
- Page 21 and 22:
Virology-2013OMICS Group is organiz
- Page 23 and 24:
111 th OMICS Group Conference3 rd I
- Page 25 and 26:
Because of heightened awareness of
- Page 27 and 28:
111 th OMICS Group Conference3 rd I
- Page 29 and 30:
111 th OMICS Group Conference3 rd I
- Page 31 and 32:
111 th OMICS Group Conference3 rd I
- Page 33 and 34:
Ara Hovanessian, J Vaccines Vaccin
- Page 35 and 36:
Nikolai Petrovsky, J Vaccines Vacci
- Page 37 and 38:
111 th OMICS Group Conference3 rd I
- Page 39 and 40:
Robert E. Sievers et al., J Vaccine
- Page 41 and 42:
Xiao-Qing Wei, J Vaccines Vaccin 20
- Page 43 and 44:
Campbell Bunce, J Vaccines Vaccin 2
- Page 45 and 46:
Hong Xin, J Vaccines Vaccin 2013, 4
- Page 47 and 48:
Diane Longo et al., J Vaccines Vacc
- Page 49 and 50:
Track 33: Novel Approaches in Desig
- Page 51 and 52:
Takashi Kei Kishimoto, J Vaccines V
- Page 53 and 54:
Benjamin Petsch, J Vaccines Vaccin
- Page 55 and 56:
A. Bennett Jenson et al., J Vaccine
- Page 57 and 58:
Milan Raska et al., J Vaccines Vacc
- Page 59 and 60:
Muhammad Ali A. Shah et al., J Vacc
- Page 61 and 62:
Track 44: Vaccines against Infectio
- Page 63 and 64:
Haval Shirwan, J Vaccines Vaccin 20
- Page 65 and 66:
Rainer Fischer, J Vaccines Vaccin 2
- Page 67 and 68:
Alwyn Rapose, J Vaccines Vaccin 201
- Page 69 and 70:
Saroj Basak, J Vaccines Vaccin 2013
- Page 71 and 72:
Gisela Gonzalez, J Vaccines Vaccin
- Page 73 and 74:
Young Research ForumSession ChairPe
- Page 75 and 76:
Humberto Hernandez et al., J Vaccin
- Page 77 and 78:
Nisha Nair et al., J Vaccines Vacci
- Page 79 and 80:
Leow Yee et al., J Vaccines Vaccin
- Page 81 and 82:
Kaissar Tabynov et al., J Vaccines
- Page 83 and 84:
Teena Mohan et al., J Vaccines Vacc
- Page 85 and 86:
Track 5 & 95: Manufacturing, Produc
- Page 87 and 88:
Graham Clarke, J Vaccines Vaccin 20
- Page 89 and 90:
Obradovic Zarema et al., J Vaccines
- Page 91 and 92:
Abdur Razzaque Sarker et al., J Vac
- Page 93 and 94:
Omer Qutaiba B. Al-lela et al., J V
- Page 95 and 96:
111 th OMICS Group Conference3 rd I
- Page 97 and 98:
Regina Heidenreich et al., J Vaccin
- Page 99 and 100: Leow Y et al., J Vaccines Vaccin 20
- Page 101 and 102: Zafer Kurugol et al., J Vaccines Va
- Page 103 and 104: Ates Kara et al., J Vaccines Vaccin
- Page 105 and 106: Yurong Tan et al., J Vaccines Vacci
- Page 107 and 108: Deryabin P.N. et al., J Vaccines Va
- Page 109 and 110: Xiao-Yong Fan et al., J Vaccines Va
- Page 111 and 112: Byung Chul Kim et al., J Vaccines V
- Page 113 and 114: STS. Chitradevi et al., J Vaccines
- Page 115 and 116: Yan Liang et al., J Vaccines Vaccin
- Page 117 and 118: 111 th OMICS Group Conference3 rd I
- Page 119 and 120: Afshineh Latifynia et al., J Vaccin
- Page 121 and 122: Hemanta Koley et al., J Vaccines Va
- Page 123 and 124: Aleksandar Masic et al., J Vaccines
- Page 125 and 126: Hassen Mamo, J Vaccines Vaccin 2013
- Page 127 and 128: Oladipo Aina et al., J Vaccines Vac
- Page 129 and 130: Aiswariya Chidambaram, J Vaccines V
- Page 131 and 132: Birhanu Hurisa et al., J Vaccines V
- Page 133 and 134: Ghaffarifar F et al., J Vaccines Va
- Page 135 and 136: Mathan Periasamy et al., J Vaccines
- Page 137 and 138: Rania Abdel Hay, J Vaccines Vaccin
- Page 139 and 140: Samuel Teshome, J Vaccines Vaccin 2
- Page 141 and 142: 111 th OMICS Group Conference3 rd I
- Page 143 and 144: Birhanu Hurisa et al., J Vaccines V
- Page 145 and 146: Dhrubajyoti Nag, J Vaccines Vaccin
- Page 147 and 148: Belachew Etana et al., J Vaccines V
- Page 149: Fatemeh Ghaffarifar et al., J Vacci
- Page 153 and 154: Prerna Chaudhary, J Vaccines Vaccin
- Page 155 and 156: Sandeepkumar R. Chauhan et al., J V
- Page 157 and 158: Veronica Rainone et al., J Vaccines
- Page 159 and 160: Page 159
- Page 161 and 162: Previous111 th OMICS Group Conferen
- Page 163 and 164: PreviousWorld Congress and Expo onB